'Some scientists' have a point:

"Some scientists have expressed caution about reading too much into topline results, which show lecanemab reduced the rate of cognitive decline in early-stage patients by 27 per cent compared with a placebo after 18 months. They said it was critical that Eisai and Biogen present full trial data and publish their findings in a peer-reviewed journal to rebuild confidence in amyloid-targeting #Alzheimer’s drugs following recent failures."

https://www.ft.com/content/bbb2e44a-af10-4926-b97b-3a26947bcb2e